Penumbra, Inc.

NYSE:PEN

Medical - Devices

Healthcare
$320.60 -0.72%

-$2.30 today

Market cap
$12.64B
Beta
0.70
P/E (TTM)
72.6
EPS (TTM)
$4.36
52W Low $221.26High $362.41

Volume 0.21M

Average 0.50M

PEN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Penumbra, Inc.NYSE: PEN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 67.9%

Gross margin was 67.9% in Q2 FY2026, up 1.9 pp from a year earlier. On a trailing-twelve-month basis it was 67.8%, up 1.4 pp year over year. Over 3 fiscal years it widened by 4.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
67.9%+0.3 pp QoQ
Last fiscal yearDec 2025
67.1%+3.9 pp YoY
LTMJun 2026
67.8%+1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.9 pp——
1 year+3.9 pp——
3 years+4.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
67.1%
Year-over-year change
+3.9pp

Gross Margin vs competitors

How PEN compares with its peers on the latest reported figures

  • PEN's LTM Jun 2026 gross margin of 67.8% is the 4th highest of the 9 companies compared; the peer median is 66.9%.
  • Its year-over-year change of +1.4 pp is the 5th highest of 9, against a peer median of +2.0 pp.
  • Over three fiscal years its change of +4.0 pp compares with a peer median of +2.5 pp.
PEN Competitors Peer median
Gross Margin for PEN and competitors
Company Period LTM level YoY 3-year change
EWEdwards Lifesciences CorporationLTM Jun 202678.0% -0.9 pp-0.2 pp
LMATLeMaitre Vascular, Inc.LTM Mar 202672.4% +3.6 pp+6.6 pp
BSXBoston Scientific CorporationLTM Jun 202671.2% +7.9 pp+8.2 pp
PENPenumbra, Inc.LTM Jun 202667.8% +1.4 pp+4.0 pp
ISRGIntuitive Surgical, Inc.LTM Sep 202667.2% +0.8 pp-1.4 pp
MDTMedtronic plcLTM Jul 202666.7% +3.3 pp-0.7 pp
ABTAbbott LaboratoriesLTM Sep 202657.1% +3.1 pp+4.4 pp
ANGOAngioDynamics, Inc.LTM Feb 202653.5% -0.9 pp+1.5 pp
MMSIMerit Medical Systems, Inc.LTM Sep 202649.4% +0.9 pp+3.6 pp
Peer median (excluding PEN) 66.9%+2.0 pp+2.5 pp

Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue747.59M847.13M1.06B1.19B1.4B
Cost of Revenue272.21M311.93M375.88M439.62M461.23M
Gross Profit475.38M535.21M682.64M755M942.44M
Gross Margin63.6%63.2%64.5%63.2%67.1%
Research & Development104.55M79.41M84.42M94.78M89.77M
Selling, General & Admin378.33M449.72M506.45M573.99M663.42M
Operating Expenses482.88M529.13M609.09M668.77M753.19M
Depreciation & Amortization16.41M24.32M27.26M23.7M17.47M
EBITDA7.84M29.96M108.65M45.99M223.91M
EBITDA Margin1.0%3.5%10.3%3.8%16.0%
Operating Income(7.5M)6.08M73.55M86.22M189.25M
Operating Margin-1.0%0.7%6.9%7.2%13.5%
Interest Income2.87M1.89M6.83M13.69M16.29M
Interest Expense1.93M1.75M1.74M1.42M1.31M
Other Income / Expenses(3M)(2.19M)6.1M(65.36M)15.88M
Income Before Tax(10.5M)3.89M79.65M20.87M205.13M
Pre-Tax Margin-1.4%0.5%7.5%1.7%14.6%
Income Tax Expense(13.13M)5.89M(11.3M)6.86M27.44M
Net Income5.28M(2M)90.95M14.01M177.69M
Net Margin0.7%-0.2%8.6%1.2%12.7%
EPS (Basic)0.14(0.05)2.370.364.57
EPS (Diluted)0.14(0.05)2.320.364.52
Weighted Avg Shares36.76M37.84M38.4M38.63M38.92M
Weighted Avg Shares (Diluted)37.88M37.84M39.22M39.27M39.29M

Penumbra, Inc.

NYSE:PEN

Intrinsic Alpha fair value

Locked

Current Price

$320.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.